ArticleEClinicalMedicine2024

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.

Yakun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.